Clinical Trial Update: A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, reactogenicity, and immunogenicity of CVnCoV in healthy adults for COVID-19 completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• CVnCoV (CVnCoV)

Snippet

Sponsor: CureVac | Conditions: Severe Acute Respiratory Syndrome, Coronavirus | Phase 1 | Status: COMPLETED | Results posted: 2023-01-30